BACK BONE

Brand Owner (click to sort) Address Description
BACKBONE WILBUR-ELLIS COMPANY 345 California Street, 27th Floor San Francisco CA 94104 BACK BONE;Fertilizers;
BACKBONE C. R. BARD, INC. 1 Becton Drive Franklin Lakes NJ 07417 BACK BONE;A base sold as a component part of a catheter securement device;
BACKBONE Case Medical 50 West Street Bloomfield NJ 07003 BACK BONE;Medical instrument organizer specifically fitted with pockets adapted for holding medical instruments, namely, curettes, scalpels, drills, endoscopes, scissors, retractors, forceps, suction tubes, bone chisels, gouges, clamps and osteotomes;
BACKBONE Lloyd Babineau 12108 Santa Maria Ave Lakeside CA 92040 BACK BONE;A therapeutic clip-on device to alleviate snoring by preventing one from sleeping on the back;
BACKBONE SPRINGFIELD, INC. 420 West Main Street Geneseo IL 61254 BACK BONE;Firearms, excluding firearms made in whole or in part from carbon fiber;
BAQBONE BAQBONE 2875 CRESCENT PARKWAY, APT 1123 ATLANTA GA 30339 BACK BONE;Headwear; Jeggings; Shirts; Sweatpants; Underwear; Belts; Hoodies; Ties as clothing; Apparel for dancers, namely, tee shirts, sweatshirts, pants, leggings, shorts and jackets; Athletic apparel, namely, shirts, pants, jackets, footwear, hats and caps, athletic uniforms; Business wear, namely, suits, jackets, trousers, blazers, blouses, shirts, skirts, dresses and footwear; T-shirts; Women's clothing, namely, shirts, dresses, skirts, blouses;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. An agent for treatment of metabolic bone disease, which contains EPO as an active ingredient, or a method for treating a patient with metabolic bone disease, which comprises EPO, is provided. Pharmaceutical products containing EPO as the active ingredient are novel prophylactic and therapeutic agents which show an ameliorative action by healing bone and bone marrow lesions in bone disease, especially bone disease based on impaired bone metabolism, aside from the previously reported erythrocyte increasing action of EPO. Pathological states, targeted by these pharmaceutical products, are bone diseases showing metabolic bone disorders, including renal failure-associated osteodystrophy, marble bone disease, diabetic nephropathy, and osteoporosis.